Chronic intractable pericardial effusion associated with pulmonary hypertension: report of two cases

We report two cases of chronic intractable pericardial effusion associated with pulmonary hypertension. Case 1. A 35-year-old women was admitted to our hospital because of dyspnea and edema. Chest X-ray examination showed enlargement of cardiac, and pulmonary artery shadow. An electrocardiogram with high voltage of R in V1 and deep S in V5 suggested right ventricular hypertrophy. Pericardial echo-free space with dilated right ventricle was demonstrated by echocardiography. Cardiac catheterization revealed an elevated pulmonary systolic pressure of 120 mmHg. No intracardiac shunt was calculated. A diagnosis of primary pulmonary hypertension was made. Pericardial drainage diminished pericardial effusion. Soon after discharge, however, pericardial effusion increased and the patient died. Case 2. A 65-year-old man was admitted because of dyspnea. The findings of chest X-ray and echocardiography were essentially the same as Case 1. Pericardial effusion disappeared after pericardiocentesis, but appeared again one month later. Cardiac catheterization demonstrated an elevated pulmonary systolic pressure of 73 mmHg. Pulmonary-capillary-wedge pressure was normal. Pulmonary arteriogram showed occlusion of the pulmonary artery trees. A diagnosis of chronic thromboembolic pulmonary hypertension was made. Although diuretics and vasodilators decreased pulmonary-artery pressure, pericardial effusion was unchanged. We compared these two cases with 11 control patients of pulmonary hypertension without pericardial effusion. Venous pressure was higher than that in the controls in Case 1, but not different in Case 2. Thus, venous pressure did not fully account for pericardial effusion. In summary, chronic pulmonary hypertension should be added to the list of conditions known to cause pericardial effusion. In these cases, echocardiography revealed important signs, and cardiac catheterization was essential for definite diagnosis. Pericardial effusion associated with pulmonary hypertension was refractory to diuretics and vasodilators.     

Can echocardiographic evaluation of cardiopulmonary hemodynamics decrease right heart catheterizations in end-stage heart failure patients awaiting transplantation?

Candidacy for heart transplantation is influenced by the severity of pulmonary hypertension. In this study, invasive hemodynamics from right-sided cardiac catheterization were compared with values obtained by validated equations from Doppler 2-dimensional transthoracic echocardiography. This prospective study was conducted in 40 patients with end-stage heart failure evaluated for heart transplantation or ventricular assist device implantation. Transthoracic echocardiography and right-sided cardiac catheterization were performed within 4 hours. From continuous-wave Doppler of the tricuspid regurgitation jet, pulmonary artery systolic pressure was calculated as the peak gradient across the tricuspid valve plus right atrial pressure estimated from inferior vena cava filling. Mean pulmonary artery pressure was calculated as (0.61 × pulmonary artery systolic pressure) + 2. Pulmonary vascular resistance (PVR) was calculated as (tricuspid regurgitation velocity/right ventricular outflow tract time-velocity integral × 10) + 0.16. Pulmonary capillary wedge pressure was calculated as 1.91 + (1.24 × E/E'). Pearson's correlation and Bland-Altman analysis of mean differences between echocardiographic and right-sided cardiac catheterization measurements were statistically significant for all hemodynamic parameters (pulmonary artery systolic pressure: r = 0.82, p < 0.05, mean difference 3.1 mm Hg, 95% confidence interval [CI] -0.2 to 6.3; mean pulmonary artery pressure: r = 0.80, p < 0.05, mean difference 2.5 mm Hg, 95% CI 0.3 to 4.6; PVR: r = 0.52, p < 0.05, mean difference 0.8 Wood units, 95% CI 0.3 to 1.4; pulmonary capillary wedge pressure: r = 0.65, p < 0.05, mean difference 2.2 mm Hg, 95% CI 0.1 to 4.3). Compared with right-sided cardiac catheterization, PVR by Doppler echocardiography identified all patients with PVR > 4 Wood units (n = 4), 73% of patients with PVR <2 Wood units (n = 8), and 52% of patients with PVR from 2 to 4 Wood units (n = 10). In conclusion, echocardiographic estimation of cardiopulmonary hemodynamics is reliable in patients with end-stage cardiomyopathy. The noninvasive assessment of hemodynamics by echocardiography may be able to decrease the number of serial right-sided cardiac catheterizations in selected patients awaiting heart transplantation. However, in patients with borderline PVR, right-sided cardiac catheterization is indicated to assess eligibility for transplantation.     

Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension.

Pulmonary hypertension associated with increased pulmonary vascular resistance (PVR) and occurring in the setting of portal hypertension is referred to as "portopulmonary hypertension." Intravenous epoprostenol (prostacyclin) is a potent pulmonary and systemic vasodilator with antithrombotic properties. It can decrease PVR and pulmonary artery pressure in patients with primary (idiopathic) pulmonary hypertension. Using right-heart catheterization, we evaluated the acute pulmonary hemodynamic effects of intravenous epoprostenol in patients with moderate to severe pulmonary hypertension (mean pulmonary artery pressure [MPAP] >/=35 mm Hg) associated with clinical manifestations of portal hypertension. Effects of long-term infusion of epoprostenol were also evaluated. We studied 15 consecutive patients with portopulmonary hypertension; 14 underwent acute administration of epoprostenol, and no significant side effects were noted. Ten patients received continuous epoprostenol (range, 8 days-30 months). Acute changes in PVR (-34% +/- 18%), MPAP (-16% +/- 10%), and cardiac output (CO) (+21 +/- 18%), were statistically significant (P <.01). Long-term use of epoprostenol further lowered PVR (-47% +/- 12% from baseline and -31% +/- 22% from the acute change; P <.05) in the 6 patients restudied by right-heart catheterization. Death occurred in 6 of 10 (60%) of those receiving long-term epoprostenol. In moderate to severe portopulmonary hypertension, intravenous epoprostenol resulted in a significant improvement (both acute and long-term) in PVR, MPAP, and CO. Potential adverse effects on portal hypertension and implications for orthotopic liver transplantation (OLT), however, require further study.     

Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension

Primary pulmonary hypertension is considered a fatal illness, with survival typically of less than four years, although survival of more than 10 years has been well documented. To assess the characteristics of patients with primary pulmonary hypertension who survive versus those who do not, 12 patients with primary pulmonary hypertension were followed, and their clinical course was documented with serial catheterization. The survivors, four male and three female, had their illness for a mean of 5.2 +/- 2 years from the time of initial catheterization, with six of the seven alive at the end of the follow-up period. The five nonsurvivors, all female, had a mean survival of 0.3 +/- 0.2 years. The nonsurviving group had significantly higher right atrial pressures (17 +/- 6 versus 6 +/- 2 mm Hg), lower cardiac indexes (1.2 +/- 0.1 versus 2.3 +/- 0.5 liters/minute/m2) and stroke volume indexes (12 +/- 7 versus 30 +/- 5 ml/beat/m2), and higher systemic resistances (64 +/- 13 versus 43 +/- 14 units) and pulmonary resistances (57 +/- 31 versus 20 +/- 4 units). The pulmonary artery pressure did not significantly differ between the groups. Using regression analysis, it was found that stroke volume index and right atrial pressure were the best independent predictors of survival, with a coefficient of determination (r2) of 83 and 72, respectively. When the initial and most recent catheterization data were compared among the survivors, no significant differences were found. Determining the stroke volume index and right atrial pressure of patients with primary pulmonary hypertension at the time of their initial presentation should help in predicting their clinical course.(ABSTRACT TRUNCATED AT 250 WORDS)     

Evaluation of the effects of vasodilator therapy in primary pulmonary hypertension. Experience in 7 cases

Primary pulmonary hypertension is an uncommon but serious disease that often results in debilitating symptoms and early death. One approach to treatment has been to attempt a reduction of pulmonary artery pressure and vascular resistance by using vasodilator drugs with conflicting results in several studies. The aim of this study is to review the ten-years (1978-1988) experience of vasodilator therapy for primary pulmonary hypertension at our institute. In this period 7 patients, 5 women and 2 men, mean age 38.4 years (range 15-66) met clinical and hemodynamic criteria for primary pulmonary hypertension. At diagnosis 3/7 patients were in NYHA class III and 2/7 in class II. Diagnosis was confirmed by open lung biopsy in one case. Mean pulmonary artery pressure was 66 +/- 17 mmHg, mean value of pulmonary vascular resistances was 22.5 +/- 11 U.W. and of cardiac index 1.8 +/- 0.58 l/min/m2. Twelve different vasodilator drugs were tested during right heart catheterization in a non randomized manner. Various vasodilators were usually tested in the same patient (2 or more drugs in 6 patients). Only one patient did not tolerate acute therapy because of development of a persistent systemic hypotension. Hemodynamic responses to nitrates showed a general reduction in pulmonary artery pressure and pulmonary vascular resistances with marginal changes in cardiac index. Calcium channel-blocking agents elicited different responses in similar patients with favorable, little, no or adverse effects in pulmonary hemodynamics and sometimes a significant decrease in systemic vascular resistances. Also hydralazine showed favorable hemodynamic results in few cases but exacerbated pulmonary hypertension in others.(ABSTRACT TRUNCATED AT 250 WORDS)     

Underlying aetiology of pulmonary hypertension in 191 patients: a single centre experience

Background and objective: The aim of this study was to describe the prevalence and annual incidence, as well as the aetiology of pulmonary hypertension (PHT) in a PHT clinic, so as to assist in future assessments of the economic burden of PHT. Methods: The medical records for all new cases of PHT, defined as systolic pulmonary artery pressure >45 mm Hg as measured by Doppler echocardiography, or as mean pulmonary artery pressure >25 mm Hg measured at cardiac catheterization, between January 1998 and December 2005, were reviewed. The aetiology of the PHT was recorded and separate mean annual incidences were calculated. Results: The study population included 191 patients ranging in age from 16 to 90 years. Respiratory disorders were the leading aetiology for PHT, accounting for 31% of cases, followed by collagen vascular diseases (19%), idiopathic (12%), haemodialysis (13%), chronic thromboembolism (8%), haematological diseases (7%), liver cirrhosis (6%) and hypoventilation syndrome (4%). The mean annual incidence of PHT was 15.9 new cases per million citizens per year, with a mean annual incidence due to respiratory disease of 4.82 (COPD, 3.83), collagen vascular disease 3.08, haemodialysis 2.08, idiopathic 1.92, chronic thromboembolism 1.33, haematological disease 1.17, liver disease 0.92 and hypoventilation syndrome 0.58. The mean annual incidence of PAH and chronic thromboembolic PHT that fitted the guidelines for therapy was 8.58 cases per year per million citizens. Conclusion: The current data may help in estimating the economic burden of PHT.     

Portopulmonary hypertension: Results from a 10-year screening algorithm

Portopulmonary hypertension (POPH) is the elevation of pulmonary artery pressure due to increased resistance to pulmonary blood flow in the setting of portal hypertension. Increased mortality has occurred with attempted liver transplantation in such patients and thus, screening for POPH is advised. We examined the relationship between screening echocardiography and right heart catheterization determinations of pressure, flow, volume, and resistance. A prospective, echocardiography-catheterization algorithm was followed from 1996 to 2005. Consecutive transplantation candidates underwent Doppler echocardiography to determine right ventricular systolic pressure (RVSP). Of 1,235 patients, 101 with RVSP >50 mm Hg underwent catheterization to measure mean pulmonary artery pressure (MPAP), flow via cardiac output (CO), central volume via pulmonary artery occlusion pressure (PAOP), and resistance via calculated pulmonary vascular resistance (PVR). Bland-Altman analysis suggested marked discordance between echocardiography-derived RVSP and catheterization results. All-cause pulmonary hypertension (MPAP >25 mm Hg) was documented in 90/101 (90%) patients. Using current pressure and resistance diagnostic guidelines (MPAP >25 mm Hg, PVR > or =240 dynes/s/cm(-5)), POPH was documented in 66/101 (65%) patients. Elevated MPAP was due to increased CO and/or PAOP in 35/101 (35%) patients with normal resistance (PVR <240 dynes/s/cm(-5)). The transpulmonary gradient (MPAP-PAOP) further characterized POPH in the presence of increased volume. Model for end stage liver disease (MELD) scores correlated poorly with MPAP and PVR. In conclusion, right heart catheterization is necessary to confirm POPH and frequently identifies other reasons for pulmonary hypertension (e.g., high flow and increased central volume) in liver transplantation candidates. Severity of POPH correlates poorly with MELD scores.     

Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension

The acute hemodynamic effect of intravenous ketanserin, an S2-serotonergic receptor antagonist, was evaluated during right heart catheterization in 20 patients with primary pulmonary hypertension. Pulmonary and systemic vascular resistance and pressure and cardiac output were measured before and after infusion of low and high dose ketanserin. A small decrease in pulmonary vascular resistance occurred after high dose drug infusion (28.4 to 25.0 U X m2; P less than 0.001), and mean pulmonary arterial pressure was unchanged. Decreases in systemic arterial pressure (91.9 to 85.9 mm Hg; P less than 0.0005) and systemic resistance (46.2 to 38.6 U X m2; P less than 0.001) were more pronounced. Cardiac index increased significantly (2.16 to 2.42 l/min/m2; P less than 0.01) due to reduced ventricular afterload. This study indicates that ketanserin has a small pulmonary vasodilating effect in primary pulmonary hypertension of doubtful clinical significance, similar to conventional vasodilators.     

Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease.

To assess the pulmonary and systemic hemodynamic effects of oral captopril in patients with connective tissue disease and pulmonary hypertension, we performed right heart catheterization in eight patients with diffuse systemic sclerosis, the CREST syndrome, or mixed connective tissue diseases prior to and immediately following administration of captopril (dose range 12.5 to 50.0 mg, short-term study). Four of these patients underwent repeat right heart catheterization after three to six months of oral captopril therapy (long-term study). In the short-term study, oral captopril produced a significant decrease in mean pulmonary vascular resistance from 6.2 +/- 3.6 to 4.6 +/- 3.8 units (p < 0.01). This was accompanied by a significant decrease in mean pulmonary artery pressure, mean blood pressure, mean systemic vascular resistance and a significant increase in cardiac output. Similar changes in pulmonary hemodynamics were noted in the long-term study. Thus, oral captopril is capable of producing an acute and sustained reduction in pulmonary vascular resistance in patients with pulmonary hypertension associated with the aforementioned connective tissue diseases.     

A 73-year-old man with primary pulmonary hypertension

A rare case of primary pulmonary hypertension was observed in a 73-year-old man. Angina pectoris was diagnosed at the age of 67 and he received several percutaneous coronary interventions because of refractory restenosis. He also had coronary artery bypass surgery at the age of 69. After 4 years, he again suffered from dyspnea and chest pain upon physical exertion. On admission to our hospital, a chest radiograph showed dilatation of bilateral pulmonary arteries. Moreover, echocardiography showed right ventricular dilatation and tricuspid regurgitation. Continuous wave Doppler imaging revealed a pressure gradient of 82.1 mmHg. Pulmonary capillary wedge pressure was normal, but pulmonary artery pressure was elevated upon cardiac catheterization. Because there was no apparent etiology of pulmonary hypertension, primary pulmonary hypertension was diagnosed and appropriate conventional therapy was started.     

Hemodynamic effects of inhaled nitric oxide in women with mitral stenosis and pulmonary hypertension

Mitral stenosis (MS) is associated with elevated left atrial pressure, increased pulmonary vascular resistance (PVR), and pulmonary hypertension (PH). The hemodynamic effects of inhaled nitric oxide (NO) in adults with MS are unknown. We sought to determine the acute hemodynamic effects of inhaled NO in adults with MS and PH. Eighteen consecutive women (mean age 58 +/- 15 years) with MS and PH underwent heart catheterization. Hemodynamic measurements were recorded at baseline, after NO inhalation at 80 ppm, and after percutaneous balloon valvuloplasty (n = 10). NO reduced pulmonary artery systolic pressure (62 +/- 14 mm Hg [baseline] vs 54 +/- 15 mm Hg [NO]; p <0.001) and PVR (3.7 +/- 2.5 Wood U [baseline] vs 2.2 +/- 1.4 Wood U [NO]; p <0.001). NO had no effect on mean aortic pressure, left ventricular end-diastolic pressure, left atrial pressure, cardiac output, or systemic vascular resistance. Mitral valve area increased after valvuloplasty (0.9 +/- 0.2 cm2 [baseline] vs 1.6 +/- 0.3 cm2 [postvalvuloplasty]; p <0.001). A decrease in left atrial pressure (25 +/- 4 mm Hg [baseline] vs 17 +/- 4 mm Hg [after valvuloplasty]; p <0.001) and pulmonary artery systolic pressure (58 +/- 12 mm Hg [baseline] vs 45 +/- 8 mm Hg [after valvuloplasty]; p <0.001) was observed after valvuloplasty. No change in cardiac output or PVR was observed. Thus inhaled NO, but not balloon valvuloplasty, acutely reduced PVR in women with MS and PH. This suggests that a reversible, endothelium-dependent regulatory abnormality of vascular tone is an important mechanism of elevated PVR in MS.     

Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension.

OBJECTIVE: Calcium antagonists are the only oral vasodilators shown to influence mortality in primary pulmonary hypertension, but the high doses required are often poorly tolerated. Amlodipine is a novel, relatively well tolerated, calcium antagonist. It has not been previously tested in humans with pulmonary hypertension. DESIGN: Calcium antagonists are claimed to be of benefit in the 20-30% of patients who respond--that is, whose mean pulmonary artery pressure and pulmonary vascular resistance decreased by 20% after acute administration. Increasing oral doses of amlodipine (up to 40 mg) were given and haemodynamic measurements were obtained by the use of indwelling pulmonary artery catheters 12 h after each dose. SETTING: Large teaching hospital, primary referral centre. PATIENTS: Six patients (four women; age range 37-78 years) with pulmonary hypertension (one with primary pulmonary hypertension, five with thromboembolic disease. MAIN OUTCOME MEASURES: Mean pulmonary artery pressure and pulmonary vascular resistance decreased by greater than 20% in two patients, mean pulmonary artery pressure decreased by greater than 20% in one patient with a pulmonary vascular resistance reduction of 19%. Thus, two of six patients responded to amlodipine and one partially responded. RESULTS: The whole group mean (SEM) pulmonary artery pressure decreased from 47.7 (4.2) to 41.7 (4.4) mm Hg and mean pulmonary vascular resistance from 8.6 (2.1) to 7.1 (1.8) Wood units. Cardiac output rose by a mean (range) of 4% (-20.8 to+20.8), heart rate by 8.8% (-10 to +33), and systemic systolic blood pressure decreased by 12% (-29.2 to -5.8) and diastolic blood pressure by 6.8% (-28.2 to+20.0). There were no symptoms of systemic hypotension. CONCLUSION: These results show that oral amlodipine can produce acute pulmonary vasodilatation in patients with pulmonary hypertension. Further studies are required, but amlodipine may prove to be of value in the treatment of primary pulmonary hypertension.     

改良心导管测定大鼠肺血管阻力的方法

目的 建立一种简单、可重复性强的测定正常及肺动脉高压大鼠肺血管阻力的方法.方法 雄性Sprague-Dawley( 180 ～ 200 g)大鼠45只,随机分为3组:正常对照组、低剂量野百合碱组(50 mg/kg)和高剂量野百合碱组(60 mg/kg).给予大鼠颈背部皮下一次性注射野百合碱建立肺动脉高压大鼠模型.大鼠肺动脉压力采用自制改良的末端呈圆弧形的PE- 50导管行右心导管法测定.心输出量利用热稀释法原理检测.肺血管阻力由平均肺动脉压力除心输出量得出.结果 三组大鼠肺动脉压力、心输出量及肺血管阻力的检测总成功率均分别为98％、100％和96％,组间差异无统计学意义.注射野百合碱21 d后,低、高剂量野百合碱组大鼠的平均肺动脉压均显著高于对照组[(43.1±0.8)mm Hg(1 mm Hg=0.133 kPa)、(54.8±2.2) mm Hg比(17.4±1.0) mm Hg,P均＜0.001],且高剂量组明显高于低剂量组(P＜0.001).低、高剂量野百合碱组大鼠心输出量均明显低于对照组[(77.5±6.9) ml/min、(71.0+6.7)ml/min比(126.8±3.9) ml/min,P均＜0.001],低、高剂量组间差异无统计学意义.低、高剂量野百合碱组大鼠肺血管阻力均显著高于对照组[(0.56±0.06) mm Hg·min-1·ml-1、(0.76±0.08)mm Hg·min-1·ml-1比(0.13±0.01)mm Hg- min-1·ml-1,P均＜0.001],且高剂量组明显高于低剂量组(P=0.01).结论 采用此方法检测大鼠肺血管阻力准确、可靠、操作性强,具有推广价值.     

Findings on routine right heart catheterization in patients with suspected coronary artery disease

Whether catheterization of the right heart should be performed routinely in all patients undergoing coronary angiography for assessment of coronary artery disease is controversial. To objectively assess the utility of routine right heart catheterization, hemodynamic data from 2,178 patients studied for angina having no signs, symptoms, or history of congestive heart failure were analyzed retrospectively. The salient results are as follows: 0.9% patients had unsuspected mitral valve gradients greater than or equal to 5 mm Hg; 0.4% had occult left-to-right shunts; 1% had pulmonary hypertension (pulmonary artery systolic pressure greater than or equal to 40 mm Hg) not attributable to an elevated mean pulmonary capillary wedge pressure (PCWP); 4.8% had PCWP greater than or equal to 18 mm Hg; 6% had cardiac indexes less than or equal to 2.0 L/min/m2, suggesting subclinical left ventricular failure. Overall, 14.5% of patients had at least one abnormal right-sided hemodynamic variable revealed by right heart catheterization. The frequency of abnormalities increased with increasing Canadian Cardiovascular Society grade of angina. Ten percent of grade 1, 14% of grade 2, 15% of grade 3, and 19% of patient 4 patients had at least one abnormality (phi 2 test, p less than or equal to 0.005). It is concluded that the right heart catheterization adds an important dimension to the diagnosis and treatment of patients undergoing coronary angiography for assessment of coronary artery disease and might significantly influence subsequent patient management.     

Dissecting aneurysm of the pulmonary artery with pulmonary hypertension

Pulmonary artery dissection was observed in a 64-yr-old female patient with severe pulmonary hypertension, which was probably primary (pulmonary vascular resistance, 817 dyn.s.cm-5; normal range less than or equal to 200 dyn.s.cm-5). The patient was admitted to the hospital because of severe dyspnea on exertion. Echocardiography demonstrated a dissecting aneurysm of the pulmonary artery. Right heart catheterization revealed severe pulmonary hypertension (mean pulmonary artery pressure, 64 mm Hg; normal range, 10 to 22 mm Hg); dissection of the pulmonary artery was confirmed by pulmonary arteriography. One-year follow-up was uneventful. In the literature, 28 patients with dissecting aneurysm of the pulmonary artery are reviewed. The dissection has only been diagnosed in life in one patient (by echocardiography).     

Natural history of primary pulmonary hypertension elucidated by pulmonary hemodynamics

The present study was undertaken to clarify the natural history of primary pulmonary hypertension (PPH) from a hemodynamic point of view. The subjects consisted of 83 patients (18 men and 65 women), whose ages ranged from 14 to 69 years and averaged 33 years. They were contacted through a nationwide survey. All patients underwent right-sided cardiac catheterization; cardiac output was measured in 52 patients and pulmonary capillary wedge pressure, in 40 patients. The following results were obtained. 1. The patients who died within three months of their cardiac catheterization were in severe right ventricular failure as shown by their elevated right atrial pressures and decreased cardiac indices. 2. The patients who died suddenly within two years of their cardiac catheterization had the same degree of right ventricular failure. The only difference was severe hypoxia in the patients with cardiac failure (54 +/- 21 vs 66 +/- 4 mmHg, p less than 0.05). 3. The patients who survived more than two years had normal right ventricular function. 4. Among the hemodynamic variables used to estimate prognosis; namely, pulmonary artery diastolic pressure, pulmonary capillary wedge pressure, cardiac index, pulmonary vascular resistance and pulmonary to systemic vascular resistance ratio, the cardiac index was the best predictor of prognosis.     

Approach to patients with heart failure and pulmonary hypertension

Opinion statement Pulmonary hypertension (PH), defined as a mean pulmonary artery pressure greater than 25 mm Hg, is not a diagnosis, but rather the physiologic consequence of the interaction between pulmonary blood flow, pulmonary vascular impedance, and downstream pulmonary venous pressure. The diagnosis and appropriate treatment of PH in patients with or without heart failure (HF) requires an understanding of the underlying pathogenesis, whether it be due to increased pulmonary venous pressure, increased pulmonary vascular resistance (PVR), increased pulmonary blood flow, or a combination thereof. Furthermore, an explanation for the underlying cause must also be sought. For example, a rise in pulmonary venous pressure may relate primarily to an increase in left ventricular end-diastolic pressure in a patient with a known cardiomyopathy; however, it may be complicated by severe mitral regurgitation. Similarly, an increased PVR may reflect reactive changes in the pulmonary vasculature due to long-standing pulmonary venous hypertension, concomitant hypoxemia/hypercapnia, or it may be the harbinger of chronic thromboembolic disease. It is imperative that reversible causes of PH be considered. Although most often diagnosed by Doppler echocardiography, full hemodynamic characterization of PH requires right heart catheterization to measure biventricular filling pressures and PVR. Integration of invasive pulmonary hemodynamics with an assessment of right ventricular function is essential to appreciate the clinical and prognostic significance of PH of an individual patient. Right heart catheterization is not practically feasible in all patients with HF and PH; however, at a minimum it should be performed in patients with a Doppler-estimated pulmonary artery pressure greater than 60 mm Hg, those who present clinically with predominant right HF, significant mitral valve disease, and in particular, patients with impaired right ventricular function.     

Present ways of diagnosing and treatment of pulmonary hypertension in the Czech Republic

Pulmonary hypertension is a condition characterized by elevation of the mean blood pressure in pulmonary artery above 25 mm Hg at rest or above 30 mm Hg during exercise. Pulmonary hypertension signs are not specific. They are frequently camouflaged by signs of a primary disease causing pulmonary hypertension. That causes difficulties with diagnosing and often doesn't lead to recognition of pulmonary hypertension till pressure in pulmonary artery is difficult to manage therapeutically. Treatment of secondary pulmonary hypertension tries to affect primary disease. In patients with pulmonary artery hypertension with preserved vasoreactivity so called conventional treatment is still recommended (vasodilatation treatment with calcium channels blockers, anticoagulation, oxygentherapy, treatment of heart failure). New ways of pharmacotherapy represent administration of prostacyclin, antagonists of endothelin receptors, and phosphodiesterase inhibitors. Nonpharmacology treatment of pulmonary hypertension includes balloon atrial septostomy, lung transplantation, and in chronic thromboembolic pulmonary hypertension pulmonary endarterectomy. Current recommendations for pulmonary hypertension treatment concentrate especially on patients in functional classes NYHA III and IV. In less symptomatic patients there is usually lack of unambiguous clinical data needed for treatment. Owning to seriousness of the disease, its difficult diagnosing and frequently difficult treatment the global trend is to concentrate care of patients with pulmonary hypertension in specialised centers. This problem systematically addresses a center at the 2nd Clinic of Internal Medicine of the 1st Medical Faculty of the Charles University and the General Teaching Hospital in Prague in close cooperation with the Clinic of Cardiovascular Surgery at the General Teaching Hospital in Prague, and the transplantation center at the 3rd Surgical Clinic of the Teaching Hospital Motol in Prague, the Czech Republic.     

Hemodynamic characterization of patients with severe emphysema

In 120 patients with severe emphysema evaluated for participation in the National Emphysema Treatment Trial, pulmonary hemodynamics and ventricular function were assessed. Pulmonary function tests were (%predicted): FEV(1) = 27%; residual volume = 224.6%; diffusion capacity = 26.7%. In 90.8% of patients, end-expiratory pulmonary artery mean pressure was > 20 mm Hg; in 61.4%, end-expiratory wedge pressure was > 12 mm Hg. Cardiac index was normal. Mean pulmonary artery pressure correlated inversely with arterial PO(2), and severity of emphysema, and directly with wedge pressure. Multiple stepwise regression revealed that arterial PO(2) was not an independent predictor of mean pulmonary artery pressure. No correlation was found between indices of emphysema severity and PA pressures. Diastolic ventricular pressures were increased without evidence of systolic dysfunction. We conclude that (1) elevations of pulmonary vascular pressures are common, (2) pulmonary hypertension may be related to factors other than hypoxia, (3) pulmonary hypertension does not impair resting systemic O(2) delivery, and (4) elevated cardiac diastolic pressures do not represent systolic dysfunction.